P A Kovalchuk, A G Dedkov, L V Bororov, B V Maksymenko
{"title":"[SURGICAL TREATMENT OF PATIENTS FOR METACHRONOUS METASTASES OF PULMONARY OSTEOSARCOMA. CLINICAL PROGNOSTIC FACTORS].","authors":"P A Kovalchuk, A G Dedkov, L V Bororov, B V Maksymenko","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The impact of surgical method on results of complex treatment in patients, suffering the osteosarcoma metachronous pulmonary metastases, was studied. The survival indices in 93 patients were analyzed, of them in 71, suffering osteosarcoma - with complex treatment, including surgical intervention of complete excision of all metastases (three-years survival – 34.2%), and in 21 – complex treatment with palliative radiation therapy (three-year survival 3.7%). Trustworthy impact on three-years survival indices was proved for such clinical factors, as the terms of the metastases occurrence (6 mo and lesser, and more, than 6 mo) and quantity of metastases (up to 5, 5 and more) present.</p>","PeriodicalId":32618,"journal":{"name":"Klinichna khirurgiia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinichna khirurgiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The impact of surgical method on results of complex treatment in patients, suffering the osteosarcoma metachronous pulmonary metastases, was studied. The survival indices in 93 patients were analyzed, of them in 71, suffering osteosarcoma - with complex treatment, including surgical intervention of complete excision of all metastases (three-years survival – 34.2%), and in 21 – complex treatment with palliative radiation therapy (three-year survival 3.7%). Trustworthy impact on three-years survival indices was proved for such clinical factors, as the terms of the metastases occurrence (6 mo and lesser, and more, than 6 mo) and quantity of metastases (up to 5, 5 and more) present.